Vistagen reports preliminary positive OLE data for fasedienol in SAD
Preliminary PALISADE-4 open-label extension data for fasedienol nasal spray suggest it was well-tolerated up to 12 months, with exploratory improvements on LSAS and SPIN over four months. Company plans to meet the FDA to consider a new registrational Phase 3.
Vistagen reported preliminary positive open-label extension data from PALISADE-4, with fasedienol nasal spray said to be well tolerated for up to 12 months. The company said exploratory results showed improvements on LSAS and SPIN over four months. Vistagen said it plans to meet with the FDA to consider a new registrational Phase 3 Material De…